Ongoing Clinical Trials for Endometrial Stromal Sarcoma
Currently, there is one ongoing clinical trial investigating treatment approaches for patients with advanced or metastatic low-grade endometrial stromal sarcoma. This trial focuses on comparing the effects of continuing versus stopping aromatase inhibitor therapy, which are medications that reduce estrogen levels in the body to help control cancer growth.
Clinical trial locations
Study on Stopping or Continuing Anastrozole, Letrozole, and Exemestane for Patients with Advanced or Metastatic Low-Grade Endometrial Stromal Sarcoma
This clinical trial is investigating an important question for patients with low-grade endometrial stromal sarcoma: is it better to continue or stop taking aromatase inhibitors once the disease is under control? The study compares outcomes between patients who maintain their treatment and those who interrupt it.
Who can participate:
- Female patients aged 18 years or older
- Patients with confirmed low-grade endometrial stromal sarcoma that has spread beyond the uterus, is locally advanced, or has returned after initial treatment
- Patients who have been taking an aromatase inhibitor (Anastrozole, Letrozole, or Exemestane) for at least 24 months if there is no measurable disease remaining, or at least 36 months if measurable disease is present
- Patients whose disease is currently under control, meaning it is either responding to treatment or remains stable
- Patients with an ECOG Performance Status of 2 or less, which means they are capable of self-care even if unable to work
- Patients with medical insurance coverage
Who cannot participate:
- Patients without a diagnosis of locally advanced or metastatic low-grade endometrial stromal sarcoma
- Male patients
- Patients younger than 18 years
- Patients who are part of a vulnerable population and may have difficulty understanding or consenting to the study
Main focus of the trial:
The primary goal is to determine whether continuing aromatase inhibitor treatment provides better control of the disease compared to stopping it. Researchers will monitor how long patients remain free from cancer progression, known as progression-free survival. The study will also evaluate overall survival, safety, quality of life, and the time until additional chemotherapy treatment becomes necessary. Patients will be randomly assigned to either continue their current medication or stop taking it, and will receive regular check-ups to monitor their health and disease status.
Investigational drugs:
The trial involves three aromatase inhibitors: Anastrozole (also known as Arimidex), Letrozole, and Exemestane (also known as Aromasin). These medications work by blocking an enzyme called aromatase, which converts other hormones into estrogen. By lowering estrogen levels in the body, these drugs can help slow the growth of cancer cells that depend on estrogen to grow. Patients take these medications orally as tablets, with dosages of 1 mg for Anastrozole and 25 mg for Exemestane. The study is expected to conclude by January 2028.
Summary
There is currently one active clinical trial for endometrial stromal sarcoma, taking place in France. This study addresses an important clinical question about the optimal duration of aromatase inhibitor therapy for patients whose disease is under control. The trial focuses specifically on low-grade endometrial stromal sarcoma, a rare and slow-growing form of uterine cancer. By comparing the outcomes of continuing versus stopping hormone therapy, this research aims to provide valuable guidance for treatment decisions and may help improve quality of life for patients by identifying the most effective management strategy. The study highlights the ongoing effort to refine treatment approaches for this rare cancer type.